Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Inhibition of Cbl-b restores effector functions of human intratumoral NK cells.

Autor: Tundo S; Department of Biomedicine, University Hospital Basel, Basel, Switzerland.; Roche Innovation Center, F. Hoffmann-La Roche AG, Roche Pharma Research and Early Development, Basel, Switzerland., Trefny M; Department of Biomedicine, University Hospital Basel, Basel, Switzerland., Rodić A; Department of Biomedicine, University Hospital Basel, Basel, Switzerland., Grueninger O; Roche Innovation Center, F. Hoffmann-La Roche AG, Roche Pharma Research and Early Development, Basel, Switzerland., Brodmann N; Roche Innovation Center, F. Hoffmann-La Roche AG, Roche Pharma Research and Early Development, Basel, Switzerland., Börsch A; Department of Biomedicine, Bioinformatics Core Facility, University of Basel, Basel, Switzerland.; Swiss Institute of Bioinformatics, Basel, Switzerland., Serger C; Department of Biomedicine, University Hospital Basel, Basel, Switzerland., Fürst J; Department of Biomedicine, University Hospital Basel, Basel, Switzerland., Buchi M; Department of Biomedicine, University Hospital Basel, Basel, Switzerland., Buczak K; Biozentrum, Proteomics Core Facility, University of Basel, Basel, Switzerland., Müller AT; Roche Innovation Center, F. Hoffmann-La Roche AG, Roche Pharma Research and Early Development, Basel, Switzerland., Sach-Peltason L; Roche Innovation Center, F. Hoffmann-La Roche AG, Roche Pharma Research and Early Development, Basel, Switzerland., Don L; Department of Biomedicine, University Hospital Basel, Basel, Switzerland., Herzig P; Department of Biomedicine, University Hospital Basel, Basel, Switzerland., Lardinois D; Department of Thoracic Surgery, University Hospital Basel, Basel, Switzerland., Heinzelmann-Schwarz V; Department of Gynecology and Obstetrics, University Hospital Basel, Basel, Switzerland., Mertz KD; Institute of Pathology, Cantonal Hospital Basel-Landschaft, Liestal, Switzerland., Hojski A; Department of Thoracic Surgery, University Hospital Basel, Basel, Switzerland., Schaeuble K; Department of Biomedicine, University Hospital Basel, Basel, Switzerland., Laubli H; Medical Oncology, University Hospital Basel, Basel, Switzerland., Natoli M; Department of Biomedicine, University Hospital Basel, Basel, Switzerland., Toso A; Roche Innovation Center, F. Hoffmann-La Roche AG, Roche Pharma Research and Early Development, Basel, Switzerland., Luu TT; Department of Biomedicine, University Hospital Basel, Basel, Switzerland., Zippelius A; Department of Biomedicine, University Hospital Basel, Basel, Switzerland alfred.zippelius@usb.ch andrea.romagnani@roche.com.; Medical Oncology, University Hospital Basel, Basel, Switzerland., Romagnani A; Roche Innovation Center, F. Hoffmann-La Roche AG, Roche Pharma Research and Early Development, Basel, Switzerland alfred.zippelius@usb.ch andrea.romagnani@roche.com.

Publikováno v: Journal for immunotherapy of cancer [J Immunother Cancer] 2024 Nov 17; Vol. 12 (11). Date of Electronic Publication: 2024 Nov 17.

Single-cell landscape of innate and acquired drug resistance in acute myeloid leukemia.

Autor: Wegmann R; Institute of Molecular Systems Biology, Department of Biology, ETH Zurich, Zurich, Switzerland., Bonilla X; Department of Computer Science, ETH Zurich, Zurich, Switzerland., Casanova R; Department of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland., Chevrier S; Department of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland., Coelho R; Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland., Esposito C; Institute of Molecular Life Sciences, University of Zurich, Zurich, Switzerland., Ficek-Pascual J; Department of Computer Science, ETH Zurich, Zurich, Switzerland., Goetze S; Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland.; ETH PHRT Swiss Multi-Omics Center (SMOC), Lausanne, Switzerland.; SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland., Gut G; Institute of Molecular Life Sciences, University of Zurich, Zurich, Switzerland., Jacob F; Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland., Jacobs A; Department of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland., Kuipers J; Department of Biosystems Science and Engineering, ETH Zurich, Zurich, Switzerland., Lischetti U; Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland., Mena J; Institute of Molecular Systems Biology, Department of Biology, ETH Zurich, Zurich, Switzerland., Milani ES; Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland., Prummer M; SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland.; NEXUS Personalized Health Technologies, ETH Zurich, Zurich, Switzerland., Del Castillo JS; Institute of Molecular Life Sciences, University of Zurich, Zurich, Switzerland., Singer F; SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland.; NEXUS Personalized Health Technologies, ETH Zurich, Zurich, Switzerland., Sivapatham S; Department of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland., Toussaint NC; SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland.; NEXUS Personalized Health Technologies, ETH Zurich, Zurich, Switzerland.; Swiss Data Science Center, ETH Zürich, Zurich, Switzerland., Vilinovszki O; Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland., Wildschut MHE; Institute of Molecular Systems Biology, Department of Biology, ETH Zurich, Zurich, Switzerland.; Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland.; Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland., Thavayogarajah T; Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland., Malani D; Harvard Medical School and Dana-Farber Cancer Institute, Boston, USA., Aebersold R; Institute of Molecular Systems Biology, Department of Biology, ETH Zurich, Zurich, Switzerland., Bacac M; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Zurich, Zurich, Switzerland., Beerenwinkel N; SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland.; Department of Biosystems Science and Engineering, ETH Zurich, Zurich, Switzerland., Beisel C; Department of Biosystems Science and Engineering, ETH Zurich, Zurich, Switzerland., Bodenmiller B; Department of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland.; Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland., Heinzelmann-Schwarz V; Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland., Koelzer VH; Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland.; University of Zurich, Faculty of Medicine, Zurich, Switzerland., Levesque MP; Department of Dermatology, University Hospital Zurich, Zurich, Switzerland., Moch H; Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland.; University of Zurich, Faculty of Medicine, Zurich, Switzerland., Pelkmans L; Institute of Molecular Life Sciences, University of Zurich, Zurich, Switzerland., Rätsch G; Department of Computer Science, ETH Zurich, Zurich, Switzerland.; SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland.; AI Center at ETH Zurich, Zurich, Switzerland., Tolnay M; Institute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland., Wicki A; Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland.; University of Zurich, Faculty of Medicine, Zurich, Switzerland., Wollscheid B; Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland., Manz MG; Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland. markus.manz@usz.ch., Snijder B; Institute of Molecular Systems Biology, Department of Biology, ETH Zurich, Zurich, Switzerland. snijder@imsb.biol.ethz.ch.; SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland. snijder@imsb.biol.ethz.ch., Theocharides APA; Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland. alexandre.theocharides@usz.ch.

Publikováno v: Nature communications [Nat Commun] 2024 Oct 30; Vol. 15 (1), pp. 9402. Date of Electronic Publication: 2024 Oct 30.

Predictive value of homologous recombination deficiency status for survival outcomes in primary tubo-ovarian high-grade serous carcinoma.

Autor: Zwimpfer TA; Peter MacCallum Cancer Centre, Melbourne, Australia.; Gynaecological Cancer Centre, University Hospital Basel, Basel, Switzerland., Ewald H; University Medical Library, University of Basel, Basel, Switzerland., Bilir E; Department of Global Health, Koç University Graduate School of Health Sciences, Istanbul, Turkey.; Department of Gynecologic Oncology, Koc University School of Medicine, Istanbul, Turkey.; Department of Obstetrics and Gynecology, University Hospitals Schleswig-Holstein, Campus Kiel, Kiel, Germany., Jayawardana M; Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia., Appenzeller-Herzog C; University Medical Library, University of Basel, Basel, Switzerland., Bizzarri N; UOC Ginecologia Oncologica, Dipartimento per la Salute della Donna e del Bambino e della Salute Pubblica, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy., Razumova Z; Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden., Kacperczyk-Bartnik J; Department of Obstetrics and Gynecology, Medical University of Warsaw, Warsaw, Poland., Heinzelmann-Schwarz V; Gynaecological Cancer Centre, University Hospital Basel, Basel, Switzerland., Friedlander M; Medical Oncology, Prince of Wales Hospital, Sydney, Australia., Bowtell DD; Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia., Garsed DW; Peter MacCallum Cancer Centre, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia.

Publikováno v: The Cochrane database of systematic reviews [Cochrane Database Syst Rev] 2024 Sep 23; Vol. 9. Cochrane AN: CD015896. Date of Electronic Publication: 2024 Sep 23.

Case C–76/05 Schwarz and Gootjes–Schwarz v. Finanzamt Bergisch Gladbach, Judgment of the Grand Chamber of 11 September 2007, not yet reported; Case C–318/05, Commission v.Germany, Judgment of the Grand Chamber of 11 September 2007, not yet reported; Joined Cases C–11/06 & C–12/06 Morgan v. Bezirksregierung Köln; Bucher v. Landrat des Kreises Düren Judgment of the Grand Chamber of 23 October 2007, not yet reported

Autor: Nic Shuibhne, Niamh

Publikováno v: Nic Shuibhne, N 2008, ' Case C–76/05 Schwarz and Gootjes–Schwarz v. Finanzamt Bergisch Gladbach, Judgment of the Grand Chamber of 11 September 2007, not yet reported; Case C–318/05, Commission v.Germany, Judgment of the Grand Chamber of 11 September 2007, not yet reported; Joined Cases C–11/06 & C–12/06 Morgan v. Bezirksregierung Köln ; Bucher v. Landrat des Kreises Düren Judgment of the Grand Chamber of 23 October 2007, not yet reported ' vol. 45, no. 3, pp. 771-86 .

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3094::89616c7d3b59395a789be458827bc369
https://www.pure.ed.ac.uk/ws/files/8642683/cmlrev_case_comment_education.pdf